FDC Peer Comparison

FDC Ltd. exhibits solid growth metrics and strong profitability, positioning it well among its peers in the Pharmaceuticals & Drugs sector. Notably, it presents a low debt level, making it a financially sound choice. However, compared to peers like Dr. Reddy's Laboratories and Cipla, its valuation appears less attractive, indicating potential for improvement in market perception.

• • FDC Ltd. has a competitive edge in revenue growth and profitability against its peers.
• • Dr. Reddy's Laboratories and Cipla showcase the strongest overall performance, particularly in profitability and growth.
• • FDC Ltd. is free of debt, reflecting strong fiscal health, while companies like Divi's Laboratories and Torrent Pharmaceuticals carry higher debt levels.

• • Dr. Reddy's Laboratories Ltd.: Highest ROE (21.76%) and strong revenue growth YoY (16.54%) and 3-Year (13.72%).
• • Cipla Ltd.: Robust profitability with a PE of 23.73 and solid revenue growth YoY (13.28%).
• • Mankind Pharma Ltd.: Exceptional revenue growth YoY (18.12%) and impressive profitability metrics.